Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Rotman Harris

2. Date of Event Requiring Statement (MM/DD/YYYY) 6/14/2023

3. Issuer Name and Ticker or Trading Symbol

Centessa Pharmaceuticals plc [CNTA]

(Last) (First) (Middle)

C/O CENTESSA PHARMACEUTICALS PLC, 3RD FL., 1 ASHLEY RD, ALTRINCHAM

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director _____ 10% Owner
___X___ Officer (give title below) _____ Other (specify below)
SVP Regulatory Affairs /

(Street)

CHESHIRE, X0 WA14 2DT

(City) (State) (Zip)

5. If Amendment, Date Original Filed(MM/DD/YYYY)

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares ⁽¹⁾	33500 ⁽²⁾	D

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Share Option (right to buy)	⁽³⁾	8/1/2032	Ordinary Shares ⁽¹⁾	125000.0	$4.47	D
Share Option (right to buy)	⁽⁴⁾	2/1/2033	Ordinary Shares ⁽¹⁾	49900.0	$3.85	D

Explanation of Responses:
(1)	The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
(2)	The shares reported were issued pursuant to a Restricted Share Unit ("RSU") grant issued under the Centessa Pharmaceuticals plc Amended and Restated 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one Ordinary Share of the Issuer. The RSUs shall vest and be settled in four equal annual installments with the first such annual vesting being on February 1, 2024.
(3)	25% of the shares subject to such option shall vest and become exercisable on August 1, 2023 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments on the first day of each month thereafter.
(4)	6,234 of the shares vest and become exercisable on August 1, 2023 and 1/48th of the shares subject to such option shall vest and become exercisable in 42 monthly installments on the first day of each month thereafter.

Remarks:
Exhibit 24 - Power of Attorney

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Rotman Harris C/O CENTESSA PHARMACEUTICALS PLC 3RD FL., 1 ASHLEY RD, ALTRINCHAM CHESHIRE, X0 WA14 2DT			SVP Regulatory Affairs

Signatures
/s/ Gregory Weinhoff, attorney-in-fact		6/23/2023
^**Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Grafico Azioni Centessa Pharmaceuticals (NASDAQ:CNTA)
Storico
Da Mag 2024 a Giu 2024

Grafico Azioni Centessa Pharmaceuticals (NASDAQ:CNTA)
Storico
Da Giu 2023 a Giu 2024

CNTA Centessa Pharmaceuticals PLC